Abstract

Prevalence of Hepatitis B is relatively low in developed European countries. However specific subpopulations may exist within each country with markedly different Hepatitis B burden. Roma minority is very numerous in Slovakia and their lifestyle is completely different to non-Roma population. The aim of this study is to map Hepatitis B prevalence in Roma and compare it to non-Roma population and to explore potential socio-economic and health related risk factors. Cross-sectional epidemiology study was performed in Slovakia that included randomly sampled Roma population and geographically corresponding random sampled non-Roma population. Comprehensive questionnaire about risk factors was administered and blood samples were drawn for Hepatitis B serology and virology tests. Altogether 855 participants were included. Global Hepatitis B surface Antigen (HBsAg) positivity rate was 7.7% (i.e., active Hepatitis B) and anti Hepatitis B core IgG antibody (antiHBcIgG) positivity rate was 34.6%. Roma population had significantly higher prevalence of Hepatitis B, both active chronic infection (12.4%; 95% Confidence Interval (CI) 9.58%–15.97% versus 2.8%; 95% CI 1.56%–4.91%; p < 0.0001) and antiHBcIgG positivity (52.8%; 95% CI 48.17%–57.44% versus 25.9%; 95% CI 12.56%–20.02%; p < 0.0001) Main risk factors for HBsAg positivity were Roma ethnicity, male sex and tattoo. Conclusion: There is a very high prevalence of Hepatitis B in Roma communities in Slovakia, with potential for grave medical consequences.

Highlights

  • Global estimated Hepatitis B surface Antigen (HBsAg) seroprevalence is 3.9% (95% uncertainty interval 3.4–4.6), corresponding to 291,992,000 (95% uncertainty interval 251,513,000–341,114,000)Int

  • The prevalence of HBsAg positivity was more than 4-times the prevalence of non-Roma population, antiHBcIgG positivity

  • We have found that people from Roma settlements in the eastern Slovakia have very high prevalence of Hepatitis B

Read more

Summary

Introduction

Global estimated Hepatitis B surface Antigen (HBsAg) seroprevalence is 3.9% (95% uncertainty interval 3.4–4.6), corresponding to 291,992,000 (95% uncertainty interval 251,513,000–341,114,000)Int. Global estimated Hepatitis B surface Antigen (HBsAg) seroprevalence is 3.9% (95% uncertainty interval 3.4–4.6), corresponding to 291,992,000 (95% uncertainty interval 251,513,000–341,114,000). Res. Public Health 2018, 15, 1047; doi:10.3390/ijerph15051047 www.mdpi.com/journal/ijerph. Res. Public Health 2018, 15, 1047 infections [1], which is a perceivable decrease from previously reported numbers but chronic Hepatitis

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call